Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, March 1 '25)

Image
By G.M.

 


    Am J Respir Crit Care Med

  1. KERWIN E, Yang T, Su N, Guo J, et al
    Rademikibart Treatment for Moderate-to-Severe, Uncontrolled Asthma: A Phase 2B Randomized Trial.
    Am J Respir Crit Care Med. 2025 Feb 25. doi: 10.1164/rccm.202409-1708.
    PubMed         Abstract available


    Antiviral Res

  2. BRUN J, Arman BY, Hill ML, Kiappes JL, et al
    Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
    Antiviral Res. 2025 Feb 23:106123. doi: 10.1016/j.antiviral.2025.106123.
    PubMed         Abstract available


    BMJ

  3. MACINTYRE CR, Chughtai AA, Kunasekaran M, Tawfiq E, et al
    The role of masks and respirators in preventing respiratory infections in healthcare and community settings.
    BMJ. 2025;388:e078573.
    PubMed         Abstract available


    Emerg Infect Dis

  4. UJIIE M
    Emerging Trends in Streptococcal Toxic Shock Syndrome, Japan.
    Emerg Infect Dis. 2025;31.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  5. STONE EC, Okasako-Schmucker DL, Taliano J, Schaefer M, et al
    Risk period for transmission of SARS-CoV-2 and seasonal influenza: a rapid review.
    Infect Control Hosp Epidemiol. 2025 Feb 24:1-9. doi: 10.1017/ice.2025.
    PubMed         Abstract available

  6. BREKELMANS MACM, Vlek ALM, van Dijk Y, Smilde AE, et al
    Automated surveillance of hospital-onset bacteremia and fungemia: feasibility and epidemiological results from a Dutch multicenter study.
    Infect Control Hosp Epidemiol. 2025 Feb 26:1-9. doi: 10.1017/ice.2025.
    PubMed         Abstract available


    Int J Infect Dis

  7. JOO H, Kim E, Huh K, Bae GH, et al
    Risk of Post-Acute Sequelae of COVID-19 and Oral Antivirals in Adults Aged Over 60 years: A Nationwide Retrospective Cohort Study.
    Int J Infect Dis. 2025 Feb 24:107850. doi: 10.1016/j.ijid.2025.107850.
    PubMed         Abstract available


    J Virol

  8. QIN W, Kong N, Xie S, Liu H, et al
    RNASEK interacting with PEDV structural proteins facilitates virus entry via clathrin-mediated endocytosis.
    J Virol. 2025;99:e0176024.
    PubMed         Abstract available

  9. LI W, Hangalapura BN, van den Elzen P, van den Born E, et al
    Spike gene variability in porcine epidemic diarrhea virus as a determinant for virulence.
    J Virol. 2025 Feb 26:e0216524. doi: 10.1128/jvi.02165.
    PubMed         Abstract available

  10. KEEP S, Foldes K, Dowgier G, Freimanis G, et al
    Recombinant infectious bronchitis virus containing mutations in non-structural proteins 10, 14, 15, and 16 and within the macrodomain provides complete protection against homologous challenge.
    J Virol. 2025 Feb 27:e0166324. doi: 10.1128/jvi.01663.
    PubMed         Abstract available


    Lancet Infect Dis

  11. FOCOSI D, Casadevall A
    Sipavibart: when a success changes into a failure.
    Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00812.
    PubMed        

  12. HAIDAR G, Thomas S, Loubet P, Baker RI, et al
    Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
    Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00804.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  13. FRUTOS AM, Cleary S, Reeves EL, Ahmad HM, et al
    Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:83-90.
    PubMed         Abstract available

  14. LINK-GELLES R, Chickery S, Webber A, Ong TC, et al
    Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged >/=18 Years - VISION and IVY Networks, September 2024-January 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:73-82.
    PubMed         Abstract available


    Nature

  15. SOWEMIMO A
    The racial injustice laid bare by COVID must not be forgotten.
    Nature. 2025;638:883-884.
    PubMed        

  16. SMITH J
    Daily briefing: Where did COVID-19 come from? Evidence points to raccoon dogs.
    Nature. 2025 Feb 21. doi: 10.1038/d41586-025-00583.
    PubMed        


    Radiology

  17. POHLER GH, Voskrebenzev A, Heinze ML, Skeries V, et al
    Phase-resolved Functional Lung MRI Reveals Distinct Lung Perfusion Phenotype in Children and Adolescents with Post-COVID-19 Condition.
    Radiology. 2025;314:e241596.
    PubMed         Abstract available

  18. PARRAGA G, Svenningsen S
    Seeing the Unseen: Pulmonary MRI in Children with Post-COVID-19 Condition.
    Radiology. 2025;314:e250127.
    PubMed        


    Travel Med Infect Dis

  19. FAGONI N, Stirparo G, Sechi GM, Comelli A, et al
    The leading "blended" civil medical evacuation operation (MEDEVAC) in unforeseen health emergency. From military use to civil development.
    Travel Med Infect Dis. 2025;63:102794.
    PubMed         Abstract available

  20. SAHIN OE, Kalay Z, Sari ND, Batirel A, et al
    Malaria in Turkey: A comprehensive analysis of diagnosis, treatment, and the impact of COVID-19, ten years after malaria elimination (2012-2023).
    Travel Med Infect Dis. 2025;64:102819.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »